Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region

Blood Cancer Journal

Volumn 4, Issue 4, 2014, Pages

  Sakamoto, K ^a   Imamura, T ^a   Yano, M ^a   Yoshida, H ^a   Fujiki, A ^a   Hirashima, Y ^a   Hosoi, H ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN EPSILON; CYTARABINE; DIMETHYL HISTONE H3 LYSINE 4; HISTONE; HISTONE DEMETHYLASE; LYSINE SPECIFIC DEMETHYLASE 1; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR PU 1; UNCLASSIFIED DRUG; AFF1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTO-ONCOGENE PROTEIN SPI-1; RETINOIC ACID RECEPTOR; TRANSACTIVATOR PROTEIN; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENHANCER REGION; ENZYME INHIBITION; FUSION GENE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRON; MLL AF9 FUSION GENE; MLL GENE; MOUSE; NONHUMAN; ONCOGENE; PROMOTER REGION; RARALPHA GENE; RUNX1 GENE; UPREGULATION; CELL CYCLE CHECKPOINT; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CYTARABINE; DNA-BINDING PROTEINS; DRUG SYNERGISM; HISTONES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; RECEPTORS, RETINOIC ACID; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; TRETINOIN;

EID: 84901934936     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.25     Document Type: Article

References (53)

1. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980; 77: 2936-2940.
2. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
3. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene 2001; 20: 7186-7203.
4. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood 2009; 113: 3655-3665.
5. Brown G, Hughes P. Retinoid differentiation therapy for common types of acute myeloid leukemia. Leuk Res. Treatment 2012; 2012: 939021.
6. Glasow A, Barrett A, Petrie K, Gupta R, Boix-Chornet M, Zhou DC et al. DNA methylation-independent loss of RARA gene expRes.sion in acute myeloid leukemia. Blood 2008; 111: 2374-2377.
7. Glasow A, Prodromou N, Xu K, von Lindern M, Zelent A. Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood 2005; 105: 341-349.
8. Fujiki A, Imamura T, Sakamoto K, Kawashima S, Yoshida H, Hirashima Y et al. Alltrans retinoic acid combined with 5-aza-2'-deoxycitidine induces C/EBPa expRes.sion and growth inhibition in MLL-AF9-positive leukemic cells. Biochem Biophys Res. Commun 2012; 428: 216-223.
9. Iijima K, Honma Y, Niitsu N. Granulocytic differentiation of leukemic cells with t(9;11)(p22;q23) induced by all-trans-retinoic acid. Leuk Lymphoma 2004; 45: 1017-1024.
10. Gu ZM, Wu YL, Zhou MY, Liu CX, Xu HZ, Yan H et al. Pharicin B stabilizes retinoic acid receptor-a and pRes.ents synergistic differentiation induction with ATRA in myeloid leukemic cells. Blood 2010; 116: 5289-5297.
11. Fang Y, Zhou X, Lin M, Ying M, Luo P, Zhu D et al. Inhibition of all-trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells. Mol Carcinog 2011; 50: 24-35.
12. Cassinat B, Zassadowski F, Ferry C, Llopis L, Bruck N, Lainey E et al. New role for granulocyte colony-stimulating factor-induced extracellular signal-regulated kinase 1/2 in histone modification and retinoic acid receptor a recruitment to gene promoters: relevance to acute promyelocytic leukemia cell differentiation. Mol Cell Biol 2011; 31: 1409-1418.
13. Schenk T, Chen WC, Gö llner S, Howell L, Jin L, Hebestreit K et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012; 18: 605-611.
14. Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012; 21: 473-487.
15. Meyer C, Hofmann J, Burmeister T, Grö ger D, Park TS, Emerenciano M et al. The MLL recombinome of acute leukemias in 2013. Leukemia 2013; 27: 2165-2176.
16. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: Res.ults of an international retrospective study. Blood 2009; 114: 2489-2496.
17. Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia 2011; 25: 1239-1248.
18. von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010; 28: 2682-2689.
19. Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, de Menezes RX et al. Gene expRes.sion profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood 2010; 115: 2835-2844.
20. Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 2009; 114: 5490-5498.
21. Niitsu N, Hayashi Y, Sugita K, Honma Y. Sensitization by 5-aza-2'-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and 1alpha,25-dihydroxyvitamin D3. Br J Haematol 2001; 112: 315-326.
22. Yoshida H, Imamura T, Fujiki A, Hirashima Y, Miyachi M, Inukai T et al. Post-transcriptional modulation of C/EBPa prompts monocytic differentiation and apoptosis in acute myelomonocytic leukemia cells. Leuk Res. 2012; 36: 735-741.
23. Leroy P, Nakshatri H, Chambon P. Mouse retinoic acid receptor alpha 2 isoform is transcribed from a promoter that contains a retinoic acid Res.ponse element. Proc Natl Acad Sci USA. 1991; 88: 10138-10142.
24. Chim CS, Wong SY, Pang A, Chu P, Lau JS, Wong KF et al. Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute promyelocytic leukemia. Leukemia 2005; 19: 2241-2246.
25. Okuno Y, Huang G, Rosenbauer F, Evans EK, Radomska HS, Iwasaki H et al. Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol Cell Biol 2005; 25: 2832-2845.
26. Ng CE, Yokomizo T, Yamashita N, Cirovic B, Jin H, Wen Z et al. A Runx1 intronic enhancer marks hemogenic endothelial cells and hematopoietic stem cells. Stem Cells 2010; 28: 1869-1881.
27. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 1997; 94: 569-574.
28. Schepers H, Wierenga AT, van Gosliga D, Eggen BJ, Vellenga E, Schuringa JJ. Reintroduction of C/EBPalpha in leukemic CD34\+ stem/progenitor cells impairs self-renewal and partially Res.toRes. myelopoiesis. Blood 2007; 110: 1317-1325.
29. Kummalue T, Friedman AD. Cross-talk between regulators of myeloid development: C/EBPalpha binds and activates the promoter of the PU.1 gene. J Leukoc Biol 2003; 74: 464-470.
30. Matsushita H, Nakajima H, Nakamura Y, Tsukamoto H, Tanaka Y, Jin G et al. C/EBPalpha and C/EBPvarepsilon induce the monocytic differentiation of myelomonocytic cells with the MLL-chimeric fusion gene. Oncogene 2008; 27: 6749-6760.
31. Gombart AF, Kwok SH, Anderson KL, Yamaguchi Y, Torbett BE, Koeffler HP. Regulation of neutrophil and eosinophil secondary granule gene expRes.sion by transcription factors C/EBP epsilon and PU.1. Blood 2003; 101: 3265-3273.
32. Park DJ, Chumakov AM, Vuong PT, Chih DY, Gombart AF, Miller Jr WH et al. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. J Clin Invest 1999; 103: 1399-1408.
33. DeKoter RP, Walsh JC, Singh H. PU.1 regulates both cytokine-dependent proliferation and differentiation of granulocyte/macrophage progenitors. EMBO J 1998; 17: 4456-4468.
34. Anderson KL, Smith KA, Perkin H, Hermanson G, Anderson CG, Jolly DJ et al. PU.1 and the granulocyte-and macrophage colony-stimulating factor receptors play distinct roles in late-stage myeloid cell differentiation. Blood 1999; 94: 2310-2318.
35. Martelli MP, Pettirossi V, Manes N, Liso A, Mezzasoma M, Cecchetti F et al. Selective silencing of the NPM1 mutant protein and apoptosis induction upon ATRA in vitro treatment of AML cells carrying NPM1 mutations. Blood 2007; 110: 868.
36. Balusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U et al. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood 2011; 118: 3096-3106.
37. Schlenk RF, Dö hner K, Kneba M, Gö tze K, Hartmann F, Del Valle F et al. Gene mutations and Res.ponse to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Res.ults from the AMLSG Trial AML HD98B. Haematologica 2009; 94: 54-60.
38. Burnett AK, Hills RK, Green C, Jenkinson S, Koo K, Patel Y et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall Res.ults and Res.ults in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 2010; 115: 948-956.
39. Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH et al. The addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia. Front Oncol 2013; 3: 218.
40. Koh CP, Wang CQ, Ng CE, Ito Y, Araki M, Tergaonkar V et al. RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes. Leukemia 2013; 27: 1793-1802.
41. Huang G, Zhao X, Wang L, Elf S, Xu H, Zhao X et al. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AMLassociated RUNX1/AML1 mutations. Blood 2011; 118: 6544-6552.
42. Huang G, Zhang P, Hirai H, Elf S, Yan X, Chen Z et al. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet 2008; 40: 51-60.
43. Rodr?́guez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330-339.
44. Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F et al. PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 2010; 17: 173-185.
45. Hoemme C, Peerzada A, Behre G, Wang Y, McClelland M, Nieselt K et al. Chromatin modifications induced by PML-RARalpha repRes.s critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood 2008; 111: 2887-2895.
46. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S et al. Histone deacetylase-targeted treatment Res.toRes. retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 2001; 61: 2-7.
47. Fazi F, Zardo G, Gelmetti V, Travaglini L, Ciolfi A, Di Croce L et al. Heterochromatic gene repRes.sion of the retinoic acid pathway in acute myeloid leukemia. Blood 2007; 109: 4432-4440.
48. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119: 941-953.
49. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
50. Hou J, Wu J, Dombkowski A, Zhang K, Holowatyj A, Boerner JL et al. Genomic amplification and a role in drug-Res.istance for the KDM5A histone demethylase in breast cancer. Am J Transl Res. 2012; 4: 247-256.
51. Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M et al. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc 2009; 131: 17536-17537.
52. Wang J, Lu F, Ren Q, Sun H, Xu Z, Lan R et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 2011; 71: 7238-7249.
53. Ogasawara D, Itoh Y, Tsumoto H, Kakizawa T, Mino K, Fukuhara K et al. Lysine-specific demethylase 1-selective inactivators: protein-targeted drug delivery mechanism. Angew Chem Int Ed Engl 2013; 52: 8620-8624.